Chengdu Easton Biopharmaceuticals Co Ltd - Asset Resilience Ratio
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has an Asset Resilience Ratio of 34.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of Chengdu Easton Biopharmaceuticals Co Ltd to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See 688513 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Chengdu Easton Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Chengdu Easton Biopharmaceuticals Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.30 Billion | 34.3% |
| Total Liquid Assets | CN¥1.30 Billion | 34.30% |
Asset Resilience Insights
- Very High Liquidity: Chengdu Easton Biopharmaceuticals Co Ltd maintains exceptional liquid asset reserves at 34.30% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Chengdu Easton Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chengdu Easton Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Chengdu Easton Biopharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.96% | CN¥758.00 Million ≈ $110.92 Million |
CN¥3.80 Billion ≈ $555.75 Million |
+6.65pp |
| 2024-12-31 | 13.30% | CN¥452.35 Million ≈ $66.19 Million |
CN¥3.40 Billion ≈ $497.55 Million |
-8.86pp |
| 2023-12-31 | 22.16% | CN¥741.78 Million ≈ $108.55 Million |
CN¥3.35 Billion ≈ $489.74 Million |
+5.05pp |
| 2022-12-31 | 17.11% | CN¥516.36 Million ≈ $75.56 Million |
CN¥3.02 Billion ≈ $441.56 Million |
+0.76pp |
| 2021-12-31 | 16.35% | CN¥453.84 Million ≈ $66.41 Million |
CN¥2.78 Billion ≈ $406.11 Million |
-6.17pp |
| 2020-12-31 | 22.52% | CN¥570.00 Million ≈ $83.41 Million |
CN¥2.53 Billion ≈ $370.34 Million |
+21.34pp |
| 2013-12-31 | 1.18% | CN¥3.00 Million ≈ $438.99K |
CN¥254.86 Million ≈ $37.29 Million |
-- |
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more